Vivos Inc., a publicly traded entity on the OTC Bulletin Board, has recently disclosed its annual filing, shedding light on significant strides in its radiation oncology platform. The company, incorporated in the United States, is making notable advancements in the development of yttrium‑90 based precision radionuclide therapy, targeting both human and veterinary cancer treatments. This dual-focus approach underscores Vivos Inc.’s commitment to broadening the impact of its innovative therapies across species.
A key highlight from the recent filing is the accelerated commercial activity surrounding its veterinary product, IsoPet®. The product has witnessed a substantial increase in administered therapies, alongside an expansion in clinic certifications. This surge not only reflects the growing acceptance and demand for IsoPet® but also positions Vivos Inc. as a formidable player in the veterinary oncology market. The company’s strategic expansion in this sector is a testament to its agility and foresight in capitalizing on emerging market opportunities.
Parallel to its veterinary endeavors, Vivos Inc. is making significant headway with its human-focused RadioGel® device. The company is actively engaging with the U.S. Food and Drug Administration, preparing for an investigational device exemption. This proactive regulatory engagement is crucial for the timely advancement of RadioGel®, potentially revolutionizing precision cancer treatment for humans. The establishment of an Indian subsidiary further exemplifies Vivos Inc.’s strategic approach to manufacturing, clinical trials, and regulatory clearance, particularly in a burgeoning market like India.
Manufacturing diversification is another strategic pillar for Vivos Inc. The company’s plans to establish both domestic and international production sites are aimed at reducing reliance on a single supplier. This diversification strategy not only mitigates risk but also ensures a more resilient supply chain, crucial for the sustained growth and scalability of its products.
Intellectual property remains a cornerstone of Vivos Inc.’s strategy. The company has broadened its intellectual-property efforts, securing new patents and trademarks covering hydrogel formulations, isotope delivery, and related technologies. These advancements not only reinforce Vivos Inc.’s position in the precision cancer-treatment arena but also safeguard its innovations, ensuring a competitive edge in the market.
Despite these promising developments, Vivos Inc. faces challenges, as reflected in its financial metrics. With a close price of $0.0899 as of March 30, 2026, and a market capitalization of $43,390,000, the company’s financial health is a point of concern. The ratio price earnings stands at -12.97, indicating that the company is not currently profitable. This financial snapshot underscores the need for Vivos Inc. to translate its technological and strategic advancements into financial success.
In conclusion, Vivos Inc. is at a pivotal juncture, with significant advancements in its radiation oncology platform and strategic expansions in both the veterinary and human markets. The company’s efforts in manufacturing diversification and intellectual property protection further solidify its position in the precision cancer-treatment arena. However, the challenge remains to convert these strategic and technological advancements into financial viability. As Vivos Inc. navigates these challenges, its ability to innovate and adapt will be critical in shaping its future trajectory in the competitive landscape of cancer treatment.
